OBJECTIVE: Adverse changes in lipoprotein particle number and size are common with insulin resistance and are associated with increased cardiovascular risk. Comprehensive information regarding lipoprotein particle number and size, and how these parameters relate to body weight, insulin resistance and hyperandrogenemia is lacking in polycystic ovary syndrome (PCOS). We tested the hypothesis that PCOS is associated with atherogenic changes in lipoprotein profile independent of body weight and examined the role of insulin resistance and androgens in these atherogenic changes. DESIGN: Case-control study performed at Clinical Research Center at an Academic Medical Center in the United States. PATIENTS AND MEASUREMENTS: Fasting blood was obtained from 25 PCOS and 25 control women of similar age and body mass index (BMI). Lipoprotein particle number and size was determined by nuclear magnetic resonance and compared between the groups. RESULTS: The mean BMI for both groups was <30 kg/m(2) (P = 0·33). Women with PCOS had an increase in very low-density lipoprotein (VLDL) particle number (P = 0·005), low-density lipoprotein (LDL) particle number (P = 0·02) and a decrease in high-density lipoprotein (HDL) size (P = 0·04). LDL size was borderline decreased (P = 0·09). These differences persisted after adjustment for ethnicity, alcohol and tobacco intake and exercise. In stepwise regression models, bioavailable testosterone was the only predictor of LDL cholesterol, triglyceride, VLDL and LDL particle number. Sex hormone binding globulin (SHBG) was the only predictor of LDL and HDL size. CONCLUSIONS: Independent of body weight, PCOS was associated with changes in lipoprotein profile that increases risk for cardiovascular disease. These changes were present in a mostly nonobese group of women and were more closely related to androgens than fasting insulin.
OBJECTIVE: Adverse changes in lipoprotein particle number and size are common with insulin resistance and are associated with increased cardiovascular risk. Comprehensive information regarding lipoprotein particle number and size, and how these parameters relate to body weight, insulin resistance and hyperandrogenemia is lacking in polycystic ovary syndrome (PCOS). We tested the hypothesis that PCOS is associated with atherogenic changes in lipoprotein profile independent of body weight and examined the role of insulin resistance and androgens in these atherogenic changes. DESIGN: Case-control study performed at Clinical Research Center at an Academic Medical Center in the United States. PATIENTS AND MEASUREMENTS: Fasting blood was obtained from 25 PCOS and 25 control women of similar age and body mass index (BMI). Lipoprotein particle number and size was determined by nuclear magnetic resonance and compared between the groups. RESULTS: The mean BMI for both groups was <30 kg/m(2) (P = 0·33). Women with PCOS had an increase in very low-density lipoprotein (VLDL) particle number (P = 0·005), low-density lipoprotein (LDL) particle number (P = 0·02) and a decrease in high-density lipoprotein (HDL) size (P = 0·04). LDL size was borderline decreased (P = 0·09). These differences persisted after adjustment for ethnicity, alcohol and tobacco intake and exercise. In stepwise regression models, bioavailable testosterone was the only predictor of LDL cholesterol, triglyceride, VLDL and LDL particle number. Sex hormone binding globulin (SHBG) was the only predictor of LDL and HDL size. CONCLUSIONS: Independent of body weight, PCOS was associated with changes in lipoprotein profile that increases risk for cardiovascular disease. These changes were present in a mostly nonobese group of women and were more closely related to androgens than fasting insulin.
Authors: S Dejager; C Pichard; P Giral; E Bruckert; M C Federspield; I Beucler; G Turpin Journal: Clin Endocrinol (Oxf) Date: 2001-04 Impact factor: 3.478
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Catherine Kim; Shengchun Kong; Ronald M Krauss; Frank Z Stanczyk; Srinivasa T Reddy; Belinda L Needham; Alka M Kanaya Journal: Metab Syndr Relat Disord Date: 2015-10-02 Impact factor: 1.894
Authors: E Gourgari; M Lodish; R Shamburek; M Keil; R Wesley; M Walter; M Sampson; S Bernstein; D Khurana; C Lyssikatos; S Ten; A Dobs; A T Remaley; C A Stratakis Journal: J Clin Endocrinol Metab Date: 2015-09-15 Impact factor: 5.958
Authors: M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine Journal: Am J Physiol Endocrinol Metab Date: 2018-08-28 Impact factor: 4.310
Authors: Pirkko Korsoff; Leonie H Bogl; Päivi Korhonen; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Richard J Rose; Risto Kaaja; Jaakko Kaprio Journal: Front Endocrinol (Lausanne) Date: 2014-03-07 Impact factor: 5.555
Authors: Victor B Ribeiro; Gislaine S Kogure; Rosana M Reis; Ada C Gastaldi; João E DE Araújo; José H Mazon; Audrey Borghi; Hugo C D Souza Journal: Int J Exerc Sci Date: 2016-11-01